Abstracts

EP173/#392 HIGH-GRADE SEROUS CARCINOMA IN RISK-REDUCING SALPINGO-OOPHORECTOMY SPECIMENS OF ASYMPTOMATIC CARRIERS OF A BRCA1/2 GERMLINE PATHOGENIC VARIANT

1Iris Stroot*, 1Jan Brouwer, 2Joost Bart, 3Hanny Hollema, 4Matthi Rookus, 1Marise Wagner, 1Heban Investigators, 2Geertluida De Bock, 3Matian Moutts, 4University Medical Center Groningen, Gynecologic Oncology, Groningen, Netherlands; 2University Medical Center Groningen, Pathology, Groningen, Netherlands; 3Netherlands Cancer Institute, Epidemiology, Amsterdam, Netherlands; 4University Medical Center Groningen, Pathology, Groningen, Netherlands; 5University Medical Center Groningen, Obstetrics & Gynaecology, Groningen, Netherlands

10.1136/ijgc-2022-igcs.264

Objectives We investigated the prevalence and reproductive and clinical factors associated with high-grade serous carcinoma (HGSC) at risk-reducing salpingo-oophorectomy (RRSO) in asymptomatic BRCA1/2 germline pathogenic variant (gPV) carriers.

Methods BRCA1/2 gPV carriers who underwent RRSO between 1995 and 2018 were identified in the Hereditary Breast and Ovarian cancer in the Netherlands (HEBON) study. Pathology reports were screened and RRSO specimens with any reported epithelial abnormality and of women with HGSC after normal RRSO were histologically reviewed. Clinical characteristics of women with and without HGSC at RRSO were compared to estimate the association between risk factors and HGSC at RRSO.

Results 2557 women of which 1624 BRCA1, 930 BRCA2 and 3 women with both BRCA1/2 gPV, were included. Median age at time of RRSO was 43.0 years (range: 25.3–73.8) for BRCA1 gPV carriers and 46.8 years (range: 27.6–77.9) for BRCA2 gPV carriers. At RRSO 24 (1.5%) BRCA1 and 6 (0.6%) BRCA2 gPV carriers had HGSC. In 73.3% the primary site of HGSC was the fallopian tube. For both BRCA1 gPV and BRCA2 gPV carriers, older age at RRSO was associated with an increased risk of HGSC at RRSO, while long-term use of oral contraceptive pill (OCP) was protective.

Conclusions HGSC was detected in 1.5% (BRCA1 gPV) and 0.6% (BRCA2 gPV) of RRSO specimens from asymptomatic carriers, with most HGSC lesions found in the fallopian tube. Our results support the fallopian tube hypothesis, highlight the importance of timely RRSO and total removal of fallopian tubes and show protective effects of OCP on HGSC.

E-poster viewing: Global health/economic challenges

EP174/#1009 WOMEN LEADERSHIP IN GYNECOLOGIC ONCOLOGY DEPARTMENTS IN ISRAEL AND IN THE UNITED STATES

1Roie Alter*, 2Tamar Perri, 2Benny Brandt, 1Liron Kogan, 1Gabriel Levin. 1Hadassah Ein Kerem, Obstyn Dept., Jerusalem, Israel; 2Hadassah Medical Center, Gynecologic Oncology, Jerusalem, Israel

10.1136/ijgc-2022-igcs.265

Objectives In Israel a there is a scarcity of women in leadership positions in academic medicine despite their increasing numbers in medical training. We aim to study the proportion of women in leadership role in Gynecologic Oncology in Israel in comparison to other places of practice.